| *Sponsored
Low Float Nasdaq Biopharma (TCBP) Tops Monday's Watchlist (5 Critical Details To Consider)
December 30th Greetings, Friend!
Wow. Catch what happened Friday?
My latest alert went off in a major way after it exploded from a previous night's after hours close of $4.55 to a new 52-week high of $9.40 for an approx. surge of 106%!
Heck. It even erupted in pre-market to a high of $10.78 (approx. 136% from the previous after hours close).
That said, I’m now excited to introduce you to TC BioPharm (Nasdaq: TCBP), a clinical-stage biopharma company revolutionizing the field of immunotherapy.
Here’s a quick look at why (Nasdaq: TCBP) is making itself known to the top of my watchlist to close out the year:
#1. Breakthrough Gamma-Delta T-Cell Therapy: At the core of TC BioPharm’s mission is TCB008, the first gamma-delta T-cell therapy to reach Phase II clinical trials for acute myeloid leukemia (AML). AML is one of the most challenging cancers to treat, yet TCB008 has demonstrated significant cytotoxic effects against AML cells in early studies—all while maintaining a remarkable safety profile.
#2. AI-Driven Innovation: In partnership with Carnegie Mellon University, TC BioPharm is integrating artificial intelligence into its donor screening processes. This advanced approach not only enhances precision but also ensures scalability for their allogeneic cell therapies.
#3. A Diverse, Expanding Pipeline: Beyond oncology, TC BioPharm is advancing therapies targeting fungal infections and viral diseases. This strategic diversification broadens their market potential and positions them to address urgent global health challenges.
#4. Momentum in Clinical Trials: The company’s ACHIEVE trial is progressing rapidly, with positive safety data, expanded clinical sites, and scalable manufacturing processes that reduce costs and boost accessibility.
#5. A Low Float: With MarketWatch suggesting fewer than 600k shares outstanding, this could become a volatile situation in moments.
With its cutting-edge science, strategic partnerships, and commitment to innovation, TC BioPharm (Nasdaq: TCBP) is poised to disrupt the biopharmacuetical landscape.
Consider getting TC BioPharm (Nasdaq: TCBP) on your radar now. I'll be in touch with updates as soon as they are available.
Talk again soon.
All the best, Dane James Editor Market Pulse Today
Sources: TCBP Website. TCBP Presentation.
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) | 
No comments:
Post a Comment